A late-stage clinical trial has shown that daraxonrasib, an experimental pancreatic cancer drug, significantly improved survival and disease control in patients with advanced cancer after chemotherapy failure.
.jpeg "Understanding Prostate Cancer: India's Growing Health Challenge")
Understanding prostate cancer in India, including rising cases, symptoms, risk factors, treatment options, cost, and how innovation and healthcare advancements are shaping outcomes.
As India and the United States begin a fresh round of trade negotiations in New Delhi from June 1 to June 4, the pharmaceutical sector has emerged as one of the most closely watched areas of discussion. The talks are expected to focus on tarif...
Zydus Lifesciences gains US FDA priority review for saroglitazar in PBC, strengthening its specialty pipeline amid rising global demand for liver disease therapies.
FDA inspection flags data integrity and manufacturing lapses at Dabur plant, raising compliance risks, export concerns, and quality scrutiny in the US market.
.jpeg "China's Biotech Boom Fuels $10.5B Pfizer Deal, Shows India Gap")
China’s biotech boom drives $10.5B Pfizer-Innovent deal, highlighting global shift to innovation while exposing India’s gaps in research, funding, and licensing.
Cipla targets 50 global filings, focusing on innovation, biosimilars, and complex generics to expand US and Europe presence and strengthen chronic therapy leadership.
Novo Nordisk’s Wegovy has received approval in India for teenagers struggling with obesity, opening a new treatment option for young patients aged 12 years and above. The approval of Novo Nordisk’s Wegovy in India for teens battling obesity come...
AI-generated fake prescriptions fueling misuse of antibiotics and psychotropic drugs are becoming a growing concern in India, raising serious questions about patient safety and online medicine sales. Health experts and chemists warn that fak...
Hikal posts Q4 FY26 profit recovery driven by crop protection growth and cost actions, despite USFDA impact and one-time charges, while maintaining dividend payout.
, CDSCO.jpg "Fostering a Quality Culture in the Pharmaceutical Industry")